AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04659460 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Remote Ischemic Conditioning
Description: RIC interventions will be applied to the upper extremity calibrated to induce four, ten-minute cycles of five-minutes-ischemia and five-minutes-perfusion for a total of 20 cumulative minutes of limb ischemia, at a pressure of 250 mmHg.
Study NCT02958488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula
Study NCT04027998 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: strain and applied pressure measurement
Description: Measurement of median nerve strain and applied pressure at proximal carpal tunnel level
Study NCT03003208 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pulmonary rehabilitation
Description: An exercise and education program
Study NCT00847366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: All patients should continue therapy on their current regimen until disease progression. The trial specific intervention is specified in the arms descriptions.
Study NCT00847366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab was given 6mg/kg i.v. daily or 2 mg/kg i.v. on day 1, 8 and 15.
Study NCT00847366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Endocrine therapy with tamoxifen will be evaluated in combination with perifosine to determine if the combination overcomes resistance to endocrine therapy .
Study NCT04196868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Description: 1500 mg once a day, per os, during six months
Study NCT04196868 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: per os, during six months
Study NCT04196868 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate treatment
Description: per os
Study NCT04196868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate treatment
Description: per os
Study NCT00367042 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Scalpel for tissue scoring
Description: During Mohs surgery we will compare the outcomes of scarring, to determine whether a mark (with a pen) or a score with a scalpel will receive the best scar.
Study NCT00367042 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Surgical marker for tissue marking
Description: You will be asked to participate, examined, discuss participation have procedure and come in for follow up for photos and check up.
Study NCT02723123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recording of cardio-respiratory signals
Description: Biological signals: ECG, RIP, SpO2 and Pulse rate will be recorded during the interventions and analyzed offline.
Study NCT02072031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib p.o. qd
Study NCT02072031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib maleate
Description: Sunitinib 50 mg p.o. qd
Study NCT02936141 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Description: Includes a group (up to 10 participants) weekly session with a duration of 90 minutes where it is stimulated communication, adaptative behaviour and social living
Study NCT03937583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose 18F
Description: The performance of the 18 FDG PET-CT will require fasting of at least 6 hours, and the glycemia will have to be lower than 126 mg / dL before the injection of 3-5 MBq / kg of 18FDG. Intravenous injection will follow a period of approximately 60 minutes in a quiet room.~Computed tomography (CT) will be performed from the middle of the forehead to the feet with normal and shallow breathing using a low dose adjustment Iodinated contrast will not be administered intravenously.
Study NCT00144482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin
Description: 36000IU（0.5mL）s.c./week for 8 weeks
Study NCT00144482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: recombinant human erythropoietin placebo
Description: 0 IU(0.5mL)s.c./week for 8 weeks
Study NCT00745563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fertiligent
Description: Fertility treatment by using the EVIE - Slow Release Insemination method
Study NCT00776607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NovoMix 30
Description: Insulin arm: Patients will be given advice on diet and exercise and life style and will be started on NovoMix 30, one dose of 6 U at the evening/main meal. Dose will be adjusted in increments of 2-6U depending on fasting glucose level When total dose equals 16 U patient will be started on 4 units with breakfast and continue with 16 units with evening meal. Breakfast and/or evening meal dose will be adjusted where necessary at increments of 2-6 U depending on fasting and/or pre-evening meal glucose level. Patient needs to keep a daily diary of insulin doses taken.
Study NCT00776607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tablet treatment
Description: Step 1: Lifestyle modification. If HbA1c at 7%+ or if on metformin/sulphonylurea go to step 2. Step 2: Glucophage. If HbA1c of 7%-7.5% give 500mg x 1 per day. If HbA1c 7.6%-8.0%, week 1 - 500mg x 1 day and then 500mg x 2 day. If HbA1c 8.0%+ then 500mg x 3 per day (Titrated). If HbA1c remains 7%+ give additional tablet until 2gms per day then progress to Step 3. Step 3: Rosiglitazone. HbA1c of 7%+ give 4 mg per day. If HbA1c remains 7%+ titrate to maximal dose 4 mg twice daily +/-Metformin. If HbA1c remains 7% + for an 3 months move to step 4. Before initiation of Rosiglitazone repeat medical history with special emphasis on cardiovascular disease, if patient has a history of CVD move to Step 4 (insulin). Any adverse events suggestive of heart disease move to step 4. Step 4: Insulin (oral agents will be stopped). Initiation of insulin will the same as for the insulin arm and will follow the protocol detailed in the Insulin arm.
Study NCT04235556 — intervention group
Intervention type: BEHAVIORAL
Intervention: Care pathway unit
Description: Patients from the prospective cohort will have their health care scheduled by the care pathway unit.
Study NCT05204264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: This intervention uses techniques based on mindfulness, metaphors and exposition exercises both in imagination and in real contexts.
Study NCT05204264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Emotional Regulation (MER)
Description: This intervention includes both formal practices of body scan meditation, standing / sitting Hatha yoga, meditations focused on the breath or other objects of attention, exercises of benevolence or kindness with affection (loving-kindness); as well as informal mindfulness practices in activities of daily living.
Study NCT00120458 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black cohosh
Description: 32 to 128 mg (black cohosh)~1 to 4 capsules daily (placebo)
Study NCT00120458 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Black cohosh
Description: 32 to 128 mg (black cohosh)~1 to 4 capsules daily (placebo)
Study NCT02627820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isis 420915/GSK 299872
Description: Open label study in comparison to historic control.
Study NCT02092571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone vaginal ring,
Description: Participants will be randomized to receive treatments in 1 of 2 treatment sequences (AB or BA)
Study NCT04406909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Access to training facility
Description: Access to training facility under national regulations for COVID control
Study NCT01738334 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator (meditation) with healthy subjects
Description: The control group with healthy subjects that was participate in meditation (active control group)
Study NCT01738334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: In the eight weeks following the first session of cognitive tests, the participants made a practice of weekly meditation group lasting 2 hours. Practices with each group (patients and active controls) occurred on different days. With regard to meditation practices were performed in a sitting posture with emphasis on daily life. Each weekly session involved meditation practices with trained professional, practical proposals for home exercise and a discussion group. Meditation compact discs (CDs)were given to participants for practices at home, which proposed activities for 5 minutes to 1 week and 2 weeks for 10 minutes 3-5, and finally 15 minutes for 6-8 weeks. After 8 weeks of treatment the second session of tests was held that involved the same tasks in session 1.
Study NCT03712397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoliposomal irinotecan
Description: combination therapy of nal-IRI , leucovorin and 5-FU in sequence at day 1, every 14 days counted as one cycle
Study NCT00847483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost 0.005% ophthalmic solution
Description: One drop in the evening in the affected eye(s) at 8:00pm
Study NCT00847483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost 004% sterile ophthalmic solution
Description: One drop in the evening in the affected eye(s) at 8:00pm
Study NCT00847483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost .03% sterile ophthalmic solution
Description: One drop in the evening in the affected eye(s) at 8:00pm
Study NCT02990442 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: repetitive transcranial magnetic stimulation, 1Hz protocol to right dorsolateral pre frontal cortex (R_DLPFC)
Study NCT01076582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE20/DRSP (YAZ, BAY86-5300)
Description: 4 cycles of treatment / per cycle: 1 tablet (EE 0.02 mg / DRSP 3 mg) daily for 24 days followed by 1 placebo tablet daily for 4 days
Study NCT01076582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethinylestradiol (EE) and desogestrel (DSG) (Mercilon)
Description: 4 cycles of treatment / per cycle: 1 tablet (EE 0.02 mg / DSG 0.15 mg) daily for 21 days followed by 1 placebo tablet daily for 7 days
Study NCT06317480 — intervention group
Intervention type: PROCEDURE
Intervention: bone resection
Description: patients underwent soft tissue sarcoma excision together with bone resection following either biological or endoprosthesis reconstruction
Study NCT06317480 — intervention group
Intervention type: PROCEDURE
Intervention: subperiosteal excision
Description: patients underwent sub-periosteal tumor excision combining bone and soft tissue ablation without bone excision
Study NCT02611986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the McGrath MAC
Description: in a randomised order we evaluate the success rate with the first attempt of the tracheal tube into the trachea.
Study NCT02611986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the Macintosh Laryngoscope
Description: in a randomised order we evaluate the success rate with the first attempt of the tracheal tube into the trachea.
Study NCT00368771 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IBS Stress Management
Description: If randomly assigned to this intervention, the session with the therapist will consist of training about IBS symptoms and their relationship to stress, as well as skills training in relaxation and ways of identifying and challenging mistaken thoughts about life events. The goal of this treatment is to lessen mental and physical stressful reactions to daily events, and therefore lessen IBS symptoms as a reaction to stress. The patient will be encouraged to apply relaxation skills to stressful situations.
Study NCT00368771 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IBS Symptom Management
Description: If assigned to this group, the therapist will discuss feelings, over-attention to IBS symptoms, and your fear of IBS symptoms. Patients will learn how to identify thoughts that may increase your IBS symptoms and will practice how to change these thoughts to ones that make them feel more comfortable. The sessions will focus on reactions to daily life that in turn result in IBS Symptoms.
Study NCT01926210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mild stimulation protocol
Description: letrozole is used from cycle day 3 to 7 and low dose recombinant FSH(no more than 150 IU/d) is used on cycle day 4,6 and 8 onwards. GnRH antagonist is only applied in case of premature LH rise might happen.
Study NCT00368771 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IBS Educational Training
Description: Those assigned to this group will be given educational materials about IBS and will discuss the reading material with the therapist. The reading topics include information on gut disorders, anatomy and physiology of the gut, assessment procedures, and how to manage IBS symptoms. Sessions will also consist of weekly reviews of daily records and IBS symptoms. The goal of this intervention is to provide educational training about IBS.
Study NCT01926210 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: controlled ovarian stimulation
Description: After fully downregulation by using short-acting GnRH agonist, 300 IU/d recombinant FSH is administrated for 5 days, then the dose is adjusted according to ovarian response.
Study NCT04521868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.
Study NCT04521868 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo is made of starch
Study NCT01963611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plovamer acetate 0.5 milligram (mg)
Description: Plovamer acetate was administered at a dose of 0.5 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
Study NCT03933865 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: HYDROmorphone Injectable Solution
Description: Hydromorphone will be given via intramuscular injection (8 mg)
Study NCT03933865 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ketamine
Description: Ketamine will be given via intramuscular injection (0.1, 0.2 or 0.4 mg/kg)
Study NCT03933865 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebos
Description: Placebo will be normal saline solution given via intramuscular injection.
Study NCT00971386 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Slow breathing
Description: The subjects will be given instructions in slow breathing at a rate of 6 to 10 breaths per minute and asked to practice it for some time. Hemodynamic measurements would be repeated before, during and after the trial of slow breathing. A Noninvasive Cardiac Output Monitor will be used. It uses a technology called impedance to measure cardiac output and other hemodynamic parameters by the passage of electric currents through the thorax. This device uses four electrode stickers applied to the thorax and the neck.
Study NCT02751840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 200 mg of caffeine capsule before RMR measurement
Study NCT02751840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine
Description: 200 mg of caffeine capsule before RMR measurement
Study NCT02751840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule (starch) before RMR measurement
Study NCT02751840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule (starch) before RMR measurement
Study NCT02751840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee
Description: 9 grams of black coffee in boiling water consumed before RMR measurement
Study NCT02751840 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Coffee
Description: 9 grams of black coffee in boiling water consumed before RMR measurement
Study NCT02751840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decaffeinated
Description: 9 grams of decaffeinated black coffee in boiling water consumed before RMR measurement
Study NCT02751840 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Decaffeinated
Description: 9 grams of decaffeinated black coffee in boiling water consumed before RMR measurement
Study NCT04747925 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mulligan two leg rotation core muscle strengthning exercises
Description: Group A :is receiving moist heat for the hamstrings muscles prior the Mulligan Two leg rotation technique for 10mins.Hold the position for 30 seconds, relax for 1 minute. Reps are given 3 repetitions. And 3 Sets at each session .core muscle strenthening exercises for back extensors and abdominals i.e Bridge curls ,table top ,abdominal crunches,back extension with arms supporting, is being performed. Position is being held for about 10 seconds and each exercise are performed with 10 repititions. Patient is being relaxed for 3 seconds between repetitions and 60 second rest between each exercise
Study NCT04747925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mulligan bent leg raise technique, core muscle strengthning exercises
Description: Group B is receiving moist heat for the hamstrings muscles prior the Mulligan Bent leg raise technique for 10 minutes. Hold the position for 30 seconds, relax for 1 minute. Reps are 3 repetitions. And 3 Sets at each session .Subject is being receive 2 weeks protocol. core muscle strenthening exercises for back extensors and abdominals i.e Bridge curls ,table top ,abdominal crunches,back extension with arms supporting, are being performed. Position is held for about 10 seconds and each exercise is performed with 10 repititions. Patient is being relaxed for 3 seconds between repetitions and 60 second rest between each exercise
Study NCT01052298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (Cipro inhale, BAYQ3939)
Description: 32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given twice daily (bid) with a concluding single dose on 11d.
Study NCT01052298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (Cipro inhale, BAYQ3939)
Description: 32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given three times daily (tid) with a concluding single dose on 11d.
Study NCT01052298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (Cipro inhale, BAYQ3939)
Description: 48.75 mg ciprofloxacin betaine corresponding to 75 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given twice daily (bid) with a concluding single dose on 11d.
Study NCT01052298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhalation powder will be given as an initial single dose inhalation on 00d.During the multiple dose phase placebo will be given twice/three-times daily with a concluding single dose on day 11d.
Study NCT03602872 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human allogeneic mesenchymal bone marrow derived stem cells
Description: Intraarticular administration of 20x10\^6 MSCs
Study NCT01816243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTS-Fentanyl
Description: Transdermal Therapeutic System (TTS)-fentanyl patches releasing fentanyl in the range of 12.5 to 100 microgram per hour (mcg/hr) rate. The initial dose of fentanyl TTS will be calculated based on each participant's opioid requirement. Patches will be usually replaced every 72 hours. Doses will be escalated in steps of 25 mcg/hr, if pain cannot be controlled. The study duration will be 30 days after first patch application.
Study NCT01816243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Participants will be allowed the use of oral morphine syrup for the duration of TTS-fentanyl treatment to enable appropriate dose titration. It is expected that most of the participants will be titrated to an appropriate dose of TTS-fentanyl within 1 week.
Study NCT00280761 — intervention group
Intervention type: DRUG
Intervention: capecitabine
Description: Capecitabine administration (where deemed appropriate by the treating medical oncologist) will commence on the second day of radiotherapy after the 24-hour biopsy has been performed. Dosing will be per current standard of care at the discretion of the treating Medical, Radiation and Surgical Oncologist
Study NCT00280761 — intervention group
Intervention type: DRUG
Intervention: 5-fluorouracil
Description: Administration of 5-fluorouracil (where deemed appropriate by the treating medical oncologist) will commence on the second day of radiotherapy after the 24-hour biopsy has been performed. Dosing and dose modification will be per current standard of care at the discretion of the treating Medical, Radiation and Surgical Oncologist.
Study NCT00280761 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical Resection
Description: Surgery will occur approximately 2-6 weeks after chemoradiation depending on clinical factors (i.e. resectability, presence or absence of metastatic disease).
Study NCT00280761 — intervention group
Intervention type: RADIATION
Intervention: Radiation therapy
Description: Dosing and dose modification will be per current standard of care at the discretion of the treating Radiation Oncologist.